Tuesday 24th April 2018
|Text too small?|
PharmaZen Ltd (PAZ), trading as Waitaki Biosciences, is a a biotechnological company based in Christchurch, New Zealand.
It is principally involved in the development, manufacture and business to business marketing of specialised nutritional ingredients for human and companion animal dietary supplement products. Exported product typically generates in excess of 90% of revenune annually.
PharmaZen offers its international customer base a portfolio of branded ingredients with specific functionality in bone and joint health, anti-inflammation, immune support, digestive health and anti-oxidant capability.
The company is chaired by Maxwell Shepherd, with Kenneth Fergus, Wayne Burt and Peter Dobbs in directorship roles.
No comments yet
NZ dollar falls with Aussie after Westpac's RBA rate cut call
Intuit juggernaut grows QuickBooks subscribers but momentum slows
Reaction to Budget rules relaxation shows balance 'about right', says Ardern
Augusta lifts net profit six fold as investors flock into new funds
Annual exports to China top $15 billion for first time
Gentrack posts $8.7M loss on CA Plus write-down
Westpac says RBNZ capital proposals would add $6,000 p.a. to an Auckland mortgage
Cavalier says market conditions still challenging
Ryman hikes dividend as annual earnings grow on wider development margin
24th May 2019 Morning Report